Your session is about to expire
← Back to Search
Beta-blocker
Timolol 0.25% Ophthalmic Solution for Wound Healing
Phase 2
Waitlist Available
Led By Keith G LeBlanc, MD
Research Sponsored by Keith G. LeBlanc, Jr, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
skin wounds greater than or equal to 4cm, closed primarily and linearly following standard excision or Mohs
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months after suture removal
Awards & highlights
Study Summary
This trial will test whether using 0.25% timolol, a topical beta-blocker, can promote wound healing in people with linear wounds longer than 4 cm.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 months after suture removal
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months after suture removal
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Observed cosmetic difference of scar in treatment side versus control: Yes or no
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: TimololExperimental Treatment1 Intervention
Timolol 0.25% applied to distal or posterior half of wound edge twice daily prior and adjunct to prior wound care.
Group II: Standard Wound CarePlacebo Group1 Intervention
Petrolatum ointment
Find a Location
Who is running the clinical trial?
Keith G. LeBlanc, Jr, MDLead Sponsor
Keith G LeBlanc, MDPrincipal InvestigatorLSU HSC New Orleans
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger